Braxia Scientific Corp. is a Canada-based medical research company. The Company is primarily focused on owning and operating multidisciplinary clinics, which provides treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. Its clinics provides ketamine and psilocybin treatments for depression and related disorders. It seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener, and Montreal. It offers Intravenous (IV) Ketamine, and Oral Ketamine Tablets. Its subsidiaries include Altmed Capital Corp., Tassili Life Science Corp., Artisan Growers Ltd., and Novo Formulations Ltd.